PRIMARY STUDY

Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review

Key Findings:  CBD is a very low-affinity agonist at CB1 that can nevertheless affect CB1 receptor activity in vivo in an indirect manner. THCV is a high-affinity antagonist at CB1 in vitro but only occasionally produces effects in vivo. THCV has also high affinity for CB2 receptors and signals as a partial agonist, differing from both CBD and rimonabant.